Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis.

Oechtering, Johanna; Schaedelin, Sabine; Benkert, Pascal; Müller, Stefanie; Achtnichts, Lutz; Vehoff, Jochen; Disanto, Giulio; Findling, Oliver; Fischer-Barnicol, Bettina; Orleth, Annette; Chan, Andrew; Pot, Caroline; Barakovic, Muhamed; Rahmanzadeh, Reza; Galbusera, Riccardo; Heijnen, Ingmar; Lalive, Patrice H; Wuerfel, Jens; Subramaniam, Suvitha; Aeschbacher, Stefanie; ... (2021). Intrathecal Immunoglobulin M Synthesis is an Independent Biomarker for Higher Disease Activity and Severity in Multiple Sclerosis. Annals of neurology, 90(3), pp. 477-489. Wiley-Blackwell 10.1002/ana.26137

[img]
Preview
Text
Oechtering__2021__Intrathecal_Immunoglobulin_M_Synthesis.pdf - Published Version
Available under License Creative Commons: Attribution-Noncommercial (CC-BY-NC).

Download (1MB) | Preview

OBJECTIVE

We aimed to determine in relapsing multiple sclerosis (MS) whether intrathecal synthesis of immunoglobulin (Ig) M and IgG is associated with outcomes reflecting inflammatory activity and chronic worsening.

METHODS

We compared cerebrospinal fluid analysis, clinical and magnetic resonance imaging data, and serum neurofilament light chain (sNfL) levels at baseline and follow-up in 530 patients with relapsing MS. Patients were categorized by the presence of oligoclonal IgG bands (OCGB) and intrathecal synthesis of IgG and IgM (intrathecal fraction [IF]: IgGIF and IgMIF ). Relationships with the time to first relapse, sNfL concentrations, T2-weighted (T2w) lesions, MS Severity Score (MSSS), and time to initiation of high-efficacy therapy were analyzed in covariate-adjusted statistical models.

RESULTS

By categorical analysis, in patients with IgMIF the median time to first relapse was 28 months shorter and MSSS on average higher by 1.11 steps compared with patients without intrathecal immunoglobulin synthesis. Moreover, patients with IgMIF had higher sNfL concentrations, more new/enlarging T2w lesions, and higher total T2w lesion counts (all p ≤ 0.01). These associations were absent or equally smaller in patients who were positive for only OCGB or OCGB/IgGIF . Furthermore, quantitative analyses revealed that in patients with IgMIF  ≥ median, the time to first relapse and to initiation of high-efficacy therapy was shorter by 32 and by 203 months, respectively (both p < 0.01), in comparison to patients with IgMIF  < median. Dose-dependent associations were also found for IgMIF but not for IgGIF with magnetic resonance imaging-defined disease activity and sNfL.

INTERPRETATION

This large study supports the value of intrathecal IgM synthesis as an independent biomarker of disease activity and severity in relapsing MS. ANN NEUROL 2021;90:477-489.

Item Type:

Journal Article (Original Article)

Division/Institute:

04 Faculty of Medicine > Department of Head Organs and Neurology (DKNS) > Clinic of Neurology

UniBE Contributor:

Chan, Andrew Hao-Kuang

Subjects:

600 Technology > 610 Medicine & health

ISSN:

1531-8249

Publisher:

Wiley-Blackwell

Language:

English

Submitter:

Chantal Kottler

Date Deposited:

30 Sep 2021 14:29

Last Modified:

30 Sep 2021 14:29

Publisher DOI:

10.1002/ana.26137

PubMed ID:

34057235

BORIS DOI:

10.48350/159332

URI:

https://boris.unibe.ch/id/eprint/159332

Actions (login required)

Edit item Edit item
Provide Feedback